Parabilis Medicines, Inc., formerly known as Cyclerion Therapeutics, Inc., is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of small-molecule therapeutics for people living with serious and orphan diseases. Parabilis leverages its deep expertise in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling pathway, specifically focusing on soluble guanylate cyclase (sGC) stimulators. These stimulators are designed to enhance the body's natural signaling to address various disease states. The company's lead therapeutic candidate, zagociguat, is a CNS-penetrant sGC stimulator currently being evaluated for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as other mitochondrial diseases where impaired signaling plays a critical role. Following its rebranding from Cyclerion in 2024, Parabilis continues to advance its clinical pipeline while seeking strategic opportunities to expand its portfolio. The company aims to address significant unmet medical needs by targeting the underlying biology of rare and debilitating conditions through precision pharmacology.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!